Brief: Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
11/12/2023 13:32
Dec 11 (Reuters) - Puma Biotechnology Inc PBYI.O :
* PUMA BIOTECHNOLOGY ANNOUNCES PHASE II CLINICAL TRIAL
DESIGN FOR
ALISERTIB IN HER2-NEGATIVE, HORMONE RECEPTOR-POSITIVE METASTATIC
BREAST CANCER
* PUMA BIOTECHNOLOGY INC - PLANS TO INITIATE TRIAL IN SECOND
HALF
OF 2024
Source text for Eikon: ID:nBw98GFNGa
Further company coverage: PBYI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Puma Biotechnology
See all newsBrief: Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(C)(4)
Brief: Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Puma Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary
Corrected: Puma Biotechnology lifts 2026 outlook as Q2 revenue rises on NERLYNX demand
Brief: Puma Biotechnology Q2 Adjusted EPS USD 0.2